Press Release Details

Corporate
Henry Schein at a Glance

Press Release Details

Henry Schein Reports Record Fourth Quarter Results

02/23/10
--Net sales up 8.0% in local currencies --Company affirms 2010 guidance
MELVILLE, N.Y., Feb 23, 2010 /PRNewswire via COMTEX/ -- Henry Schein, Inc. (Nasdaq: HSIC), the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended December 26, 2009.

Net sales for the fourth quarter of 2009 were $1.8 billion, an increase of 13.0% compared with the fourth quarter of 2008. This consists of 8.0% growth in local currencies and 5.0% growth related to foreign currency exchange (see Exhibit A for details of sales growth).

Income from continuing operations attributable to Henry Schein, Inc. for the fourth quarter of 2009 was $86.4 million or $0.94 per diluted share, an increase of 36.9% and 32.4%, respectively, compared with the fourth quarter of 2008. Current and prior-year results include certain unusual items. Excluding these items, non-GAAP income from continuing operations was $85.7 million or $0.93 per share, an increase of 8.3% and 5.7%, respectively, compared with the fourth quarter of 2008 (see Exhibit B for reconciliation of GAAP income and EPS from continuing operations to non-GAAP income and EPS from continuing operations).

"We are pleased to report growth in local currencies for each of our four business Groups, with particular strength in our International Group," said Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein. "For the year, despite a challenging macroeconomic environment we posted solid gains in net sales of 5.7% in local currencies."

Dental Group sales of $671.7 million increased 1.5%, consisting of 0.2% growth in local currencies and 1.3% growth related to foreign currency exchange. The 0.2% growth in local currencies included 4.0% growth in Dental consumable merchandise sales and a 7.2% decline in Dental equipment sales and service revenues.

"Quarterly growth in Dental consumable merchandise provides further evidence of positive market trends and the decline in sales of Dental equipment has improved for two consecutive quarters," commented Mr. Bergman.

Medical Group sales of $368.2 million increased 5.5%. Excluding sales of seasonal influenza vaccines, which declined from last year's fourth quarter, Medical Group sales increased 8.1%.

"Medical sales growth reflects strong sales of consumable products, as well as sales of products related to the treatment and prevention of the H1N1 virus," said Mr. Bergman. "During the quarter we announced the formation of Butler Schein Animal Health, which now is in operation as the leading U.S. companion animal health distribution company. On a worldwide basis, our veterinary business will represent approximately $1.4 billion in annual sales."

International Group sales of $699.1 million increased 32.4%, consisting of 19.3% growth in local currencies and 13.1% growth related to foreign currency exchange.

"For the first time ever our International Group sales were the largest of our four Groups during the quarter, as we reap the benefits of a multi-year global strategy. Once again we had double-digit sales growth in local currencies in our International dental, medical and veterinary businesses," added Mr. Bergman.

Technology and Value-Added Services Group sales of $47.1 million increased 11.2% during the quarter, consisting of 9.8% growth in local currencies and 1.4% growth related to foreign currency exchange.

"During the quarter we saw continued strong growth in electronic services, as well as solid sales of International software products," explained Mr. Bergman.

Full Year Results

For the 2009 full year, net sales of $6.5 billion represent growth of 2.5% compared with 2008. This includes 5.7% growth in local currencies and 3.2% decline related to foreign currency exchange.

Income from continuing operations attributable to Henry Schein, Inc. for 2009 was $308.6 million or $3.41 per diluted share, an increase of 24.7% and 25.8%, respectively, compared with 2008. Excluding unusual items as detailed in Exhibit B, income from continuing operations attributable to Henry Schein, Inc. for 2009 was $289.5 million or $3.20 per diluted share, an increase of 8.7% and 9.6%, respectively, compared with 2008 (see Exhibit B for reconciliation of GAAP income and EPS from continuing operations to non-GAAP income and EPS from continuing operations).

2010 EPS Guidance

Henry Schein today affirmed 2010 financial guidance, as follows:

  • 2010 diluted EPS attributable to Henry Schein, Inc. is expected to be $3.40 to $3.56.
  • Guidance for 2010 diluted EPS attributable to Henry Schein, Inc. is for current continuing operations including Butler Schein Animal Health as well as other completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any.
  • 2010 guidance excludes the impact of restructuring costs which are expected to be in the range of $10-12 million and are expected to occur primarily in the first quarter.

Fourth Quarter Conference Call Webcast

The Company will hold a conference call to discuss fourth quarter financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call over the Internet through Henry Schein's Web site at www.henryschein.com. In addition, a replay will be available beginning shortly after the call has ended.

About Henry Schein

Henry Schein, a Fortune 500(R) company and a member of the NASDAQ 100(R) Index, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 600,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items. Henry Schein also provides exclusive, innovative technology offerings for dental, medical and veterinary professionals, including value-added practice management software and electronic health record solutions.

Headquartered in Melville, N.Y., Henry Schein employs more than 13,500 people and has operations or affiliates in 23 countries. The Company's net sales reached a record $6.5 billion in 2009. For more information, visit the Henry Schein Web site at www.henryschein.com.

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: decreased customer demand and changes in vendor credit terms; disruptions in financial markets; general economic conditions; effects of a highly competitive market; changes in the healthcare industry; changes in regulatory requirements; risks from expansion of customer purchasing power and multi-tiered costing structures; risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions, including the failure to achieve anticipated synergies; financial risks associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; risks from disruption to our information systems; our dependence upon sales personnel, manufacturers and customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service issues with our third-party shippers; risks from rapid technological change; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

(TABLES TO FOLLOW)




                                         HENRY SCHEIN, INC.
                                 CONSOLIDATED STATEMENTS OF INCOME
                               (in thousands, except per share data)

                              Three Months Ended          Years Ended
                              ------------------          -----------
                          December 26, December 27, December 26, December 27,
                             2009          2008        2009         2008
                          -----------  -----------  -----------  -----------
                          (unaudited)  (unaudited)

    Net sales           $1,786,081   $1,581,179  $6,538,336    $6,380,413
    Cost of sales        1,259,809    1,116,271   4,621,516     4,506,118
                         ---------    ---------   ---------     ---------
      Gross profit         526,272      464,908   1,916,820     1,874,295
    Operating expenses:
     Selling, general
      and administrative   389,653      337,257   1,449,715     1,431,769
     Restructuring costs
     (credits)              (1,023)      23,240       3,020        23,240
                            ------       ------       -----        ------
      Operating income     137,642      104,411     464,085       419,286
    Other income
     (expense):
      Interest income        2,305        4,138       9,979        16,355
      Interest expense      (5,041)      (7,789)    (23,370)      (34,605)
      Other, net               431          (63)      2,026        (5,587)
                               ---          ---       -----        ------
       Income from
        continuing
        operations before
        taxes, equity
        in earnings of
        affiliates and
        noncontrolling
        interests          135,337      100,697     452,720      395,449
    Income taxes           (44,119)     (32,423)   (127,521)    (131,210)
    Equity in earnings
     of affiliates           1,466        1,017       5,243        5,037
                             -----        -----       -----        -----
    Income from continuing
     operations             92,684       69,291     330,442      269,276
      Income (loss) from
      discontinued
      operations, net
      of tax                     -       (7,074)      2,715       (7,902)
                               ---       ------       -----       ------
    Net income              92,684       62,217     333,157      261,374
      Less: Net income
       attributable to
       noncontrolling
       interests            (6,276)      (6,258)    (22,004)     (21,917)
                            ------       ------     -------      -------
    Net income
     attributable to
     Henry Schein, Inc.    $86,408      $55,959    $311,153     $239,457
                           =======      =======    ========     ========

    Amounts attributable
     to Henry Schein, Inc.:
     Income from
      continuing
      operations           $86,408      $63,108    $308,551     $247,347
     Income (loss)
      from discontinued
      operations, net
      of tax                     -       (7,149)      2,602       (7,890)
                               ---       ------       -----       ------
     Net income            $86,408      $55,959    $311,153     $239,457
                           =======      =======    ========     ========

    Earnings (loss) per
     share attributable
     to Henry Schein, Inc.:

    From continuing
     operations:
      Basic                  $0.97        $0.71       $3.47        $2.78
                             =====        =====       =====        =====
      Diluted                $0.94        $0.71       $3.41        $2.71
                             =====        =====       =====        =====

    From discontinued
     operations:
      Basic                  $0.00       $(0.08)      $0.03       $(0.09)
                             =====       ======       =====       ======
      Diluted                $0.00       $(0.08)      $0.03       $(0.08)
                             =====       ======       =====       ======

    From net
     income:
      Basic                  $0.97        $0.63       $3.50        $2.69
                             =====        =====       =====        =====
      Diluted                $0.94        $0.63       $3.44        $2.63
                             =====        =====       =====        =====

    Weighted-average
     common shares
     outstanding:
      Basic                 89,179       88,673      88,872       89,080
                            ======       ======      ======       ======
      Diluted               92,010       89,405      90,556       91,221
                            ======       ======      ======       ======

    Note: The above prior period amounts have been restated to reflect the
    effects of discontinued operations, the adoption of ASC Topic 470-20
    related to convertible debt and ASC Topic 810-10-65 related to the
    presentation of noncontrolling interests.



                            HENRY SCHEIN, INC.
                      CONSOLIDATED BALANCE SHEETS
               (in thousands, except share and per share data)

                                            December 26,    December 27,
                                                2009           2008
                                                ----           ----
    ASSETS
    Current assets:
        Cash and cash equivalents            $471,154        $369,570
        Accounts receivable, net of reserves
        of $51,724 and $42,855                725,397         734,027
        Inventories, net                      775,199         731,654
        Deferred income taxes                  48,001          36,974
        Prepaid expenses and other            183,782         193,841
                                              -------         -------
          Total current assets              2,203,533       2,066,066
    Property and equipment, net               259,576         247,835
    Goodwill                                  986,395         922,952
    Other intangibles, net                    204,445         214,093
    Investments and other                     182,036         148,264
                                              -------         -------
          Total assets                     $3,835,985      $3,599,210
                                           ==========      ==========

    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
        Accounts payable                     $521,079        $554,773
        Bank credit lines                         932           4,936
        Current maturities of long-term debt   23,560         156,405
        Accrued expenses:
           Payroll and related                155,298         135,523
           Taxes                               86,034          69,792
           Other                              289,351         262,236
                                              -------         -------
          Total current liabilities         1,076,254       1,183,665
    Long-term debt                            243,373         256,648
    Deferred income taxes                     100,976          95,399
    Other liabilities                          75,304          58,109
                                               ------          ------
          Total liabilities                 1,495,907       1,593,821

    Redeemable noncontrolling interests       178,570         233,035
    Commitments and contingencies

    Stockholders' equity:
      Preferred stock, $.01 par value,
       1,000,000 shares authorized,
       none outstanding                             -               -
      Common stock, $.01 par value,
       240,000,000 shares authorized,
       90,630,889 outstanding on
       December 26, 2009 and 89,351,849
       outstanding on December 27, 2008           906             894
      Additional paid-in capital              603,772         560,023
       Retained earnings                    1,492,607       1,181,454
       Accumulated other
        comprehensive income                   64,194          29,721
                                               ------          ------
       Total Henry Schein, Inc.
        stockholders' equity                2,161,479       1,772,092
       Noncontrolling interest                     29             262
                                                  ---             ---
         Total stockholders' equity         2,161,508       1,772,354
                                            ---------       ---------
         Total liabilities, redeemable
          noncontrolling interests and
          stockholders' equity             $3,835,985      $3,599,210
                                           ==========      ==========

    Note: The above prior period amounts have been restated to reflect the
    adoption of ASC Topic 480-10 related to redeemable noncontrolling
    interests, ASC Topic 470-20 related to convertible debt and ASC Topic
    810-10-65 related to the presentation of noncontrolling interests.



                                   HENRY SCHEIN, INC.
                        CONSOLIDATED STATEMENTS OF CASH FLOWS
                                     (in thousands)

                                   Three Months Ended        Years Ended
                                   ------------------        -----------
                                 December   December      December   December
                                    26,        27,           26,        27,
                                   2009       2008          2009       2008
                                 --------   --------      --------   --------
                               (unaudited) (unaudited)
    Cash flows from operating
     activities:
     Net income                  $92,684    $62,217      $333,157    $261,374
     Adjustments to reconcile
      net income to net cash
      provided by operating
      activities:
       Gain on sale of
        discontinued operation,
        net of tax                     -          -        (2,382)          -
       Depreciation and
        amortization              20,563     18,944        81,493      78,127
       Amortization of bond
        discount                   1,517      1,435         5,990       5,649
       Stock-based compensation
        expense                    7,580      2,369        25,924      25,429
       Impairment from write-down
        of long-lived assets of
        discontinued operation         -      8,484             -       8,484
       Provision for losses on
        trade and other accounts
        receivable                 1,993      2,544         4,747       6,255
       Provision for (benefit from)
        deferred income taxes      3,419     (3,253)      (26,214)     (5,958)
       Stock issued to 401(k)
        plan                           -          -         5,301       4,662
       Undistributed earnings of
        affiliates                (1,466)    (1,017)       (5,243)     (5,037)
       Other                        (162)     2,282         2,373         150
       Changes in operating
        assets and liabilities,
        net of acquisitions:
         Accounts receivable      33,233     39,917        20,445     (26,834)
         Inventories              (9,008)      (178)      (19,242)    (68,360)
         Other current assets      1,181     14,721           375      11,261
         Accounts payable
          and accrued expenses    26,979     47,653       (29,834)     89,580
                                  ------     ------       -------      ------
    Net cash provided by
     operating activities        178,513    196,118       396,890     384,782
                                 -------    -------       -------     -------

    Cash flows from investing
     activities:
      Purchases of fixed assets  (13,210)   (12,751)      (51,627)    (50,870)
      Payments for equity
       investment and business
       acquisitions, net of cash
       acquired                  (11,190)  (102,540)      (56,648)   (128,470)
      Cash received from business
       divestiture                     -          -        12,716           -
      Purchases of available-
       for-sale securities             -          -             -     (35,925)
      Proceeds from sales of
       available-for-sale
        securities                 1,225      4,150         9,955       5,722
      Net proceeds from foreign
       exchange forward contract
       settlements                     -     32,246           275      41,336
      Other                         (861)    (3,410)      (12,119)        197
                                    ----     ------       -------         ---
    Net cash used in investing
     activities                  (24,036)   (82,305)      (97,448)   (168,010)
                                 -------    -------       -------    --------

    Cash flows from financing
     activities:
      Repayments of bank
       borrowings                   (652)    (1,411)       (4,481)     (7,197)
      Principal payments for
       long-term debt               (877)    (3,582)     (154,329)    (33,721)
      Proceeds from issuance of
       stock upon exercise
       of stock options            2,181        608        11,870      25,649
      Payments for repurchases of
       common stock                    -    (27,843)            -     (82,788)
      Excess tax benefits related
       to stock-based compensation 1,859        406         4,680      11,041
      Acquisitions of
       noncontrolling interests in
       subsidiaries                    -          -       (52,453)          -
      Other                         (835)       902        (2,962)       (954)
                                    ----        ---        ------        ----
    Net cash provided by
     (used in) financing
      activities                   1,676    (30,920)     (197,675)    (87,970)
                                   -----    -------      --------     -------

    Net change in cash and cash
     equivalents                 156,153     82,893       101,767     128,802
    Effect of exchange rate
     changes on cash and
     cash equivalents             (2,606)    (1,687)         (183)    (6,822)
    Cash and cash equivalents,
     beginning of period         317,607    288,364       369,570    247,590
                                 -------    -------       -------    -------
    Cash and cash
     equivalents, end of
      period                    $471,154   $369,570      $471,154   $369,570
                                ========   ========      ========   ========

    Note:  The above prior period amounts have been restated to reflect the
    adoption of ASC Topic 470-20 related to convertible debt and ASC Topic
    810-10-65 related to the presentation of noncontrolling interests.
    Certain prior period amounts have been reclassified to conform to the
    current period presentation.



    Exhibit A

                                  Henry Schein, Inc.
                                  2009 Fourth Quarter
                              Sales Growth Rate Summary
                                     (unaudited)

                         Q4 2009 over Q4 2008
                         --------------------

                    Consolidated  Dental  Medical  International  Technology
                    ------------  ------  -------  -------------  ----------

    Internal Sales
     Growth                 3.0%   -2.5%      4.3%           8.7%        6.4%

    Acquisitions            5.0%    2.7%      1.2%          10.6%        3.4%
                            ---     ---       ---           ----         ---
      Local Currency
       Sales Growth         8.0%    0.2%      5.5%          19.3%        9.8%

    Foreign Currency
     Exchange               5.0%    1.3%      0.0%          13.1%        1.4%
                            ---     ---       ---           ----         ---

      Total Sales Growth   13.0%    1.5%      5.5%          32.4%       11.2%
                           ====     ===       ===           ====        ====

    Total Sales Growth
     excluding influenza
     vaccine sales         13.6%    1.5%      8.1%          32.4%       11.2%

    Local Currency Sales
     Growth excluding
     influenza vaccine
     sales                  8.6%    0.2%      8.1%          19.3%        9.8%


                        Q4 YTD 2009 over Q4 YTD 2008
                        ----------------------------

                   Consolidated  Dental  Medical  International  Technology
                   ------------  ------  -------  -------------  ----------

    Internal Sales
     Growth                 0.9%   -4.0%     0.8%           6.2%        6.7%

    Acquisitions            4.8%    2.4%     1.2%          10.2%        1.6%
                            ---     ---      ---           ----         ---

      Local Currency
       Sales Growth         5.7%   -1.6%     2.0%          16.4%        8.3%

    Foreign Currency
     Exchange              -3.2%   -0.6%     0.0%          -8.4%       -2.2%
                           ----    ----      ---           ----        ----

      Total Sales Growth    2.5%   -2.2%     2.0%           8.0%        6.1%
                            ===    ====      ===            ===         ===

    Total Sales Growth
     excluding influenza
     vaccine sales          3.3%   -2.2%     5.9%           8.0%        6.1%

    Local Currency Sales
     Growth excluding
     influenza vaccine
     sales                  6.6%   -1.6%     5.9%          16.4%        8.3%



    Exhibit B

                                  Henry Schein, Inc.
                              2009 Fourth Quarter and YTD
           Reconciliation of GAAP results of continuing operations to non-GAAP
                          results of continuing operations
                        (in thousands, except per share data)
                                       (unaudited)

                                Fourth Quarter    %            YTD         %
                                 2009    2008   Growth    2009    2008  Growth
                                 ----    ----   ------    ----    ----  ------
    From Continuing Operations
    --------------------------
    Income from Continuing
     Operations attributable
     to Henry Schein, Inc.    $86,408  $63,108   36.9% $308,551 $247,347 24.7%
    Diluted EPS from
     Continuing Operations
     attributable to Henry
     Schein, Inc.                0.94     0.71   32.4%     3.41     2.71 25.8%


    Non-GAAP Adjustments
     (after-tax)
    Foreign tax benefit             -        -         $(20,845)       -
    Costs related to foreign
     tax benefit                    -        -            1,080        -
    Adjustments related to
     Lehman Brothers Bankruptcy     -        -             (338)  $3,045
    Other non-recurring
     income/expense, net            -        -           (1,028)       -
    Restructuring costs
     (credits)                  $(726) $15,991            2,058    15,991
                                -----  -------            -----    ------
    Income from Continuing
     Operations attributable
     to Henry Schein, Inc.      $(726) $15,991         $(19,073)  $19,036
    Diluted EPS from
     Continuing Operations
     attributable to Henry
     Schein, Inc.               (0.01)    0.18            (0.21)     0.21

    Adjusted Results From
     Continuing Operations
    ----------------------
    Income from Continuing
     Operations attributable
     to Henry Schein, Inc.    $85,682  $79,099    8.3% $289,478  $266,383 8.7%
    Diluted EPS from
     Continuing Operations
     attributable to Henry
     Schein, Inc.                0.93     0.88    5.7%     3.20      2.92 9.6%
    ----------------------       ----     ----    ---      ----      ---- ---

    This non-GAAP comparison is being presented in order to provide a more
    comparable basis for analysis.  Earnings per share numbers may not sum due
    to rounding.



SOURCE Henry Schein, Inc.